ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Profiles of blood-brain barrier and neurodegeneration markers in cerebrospinal fluid of patients with cerebral amyloid angiopathy.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Characterisation of patients with intracerebral haemorrhage with mixed location haemorrhages: clinical and imaging features, CSF neurodegeneration markers and recurrence risk.European stroke journal · 2026Article
- Profiles of blood-brain barrier and neurodegeneration markers in cerebrospinal fluid of patients with cerebral amyloid angiopathy.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThere are few studies analyzing cerebrospinal fluid (CSF) in patients with cerebral amyloid angiopathy (CAA). Our goal was to compare blood-brain barrier and neurodegeneration markers in CSF in CAA patients with and without hemorrhagic markers.
methodsIn a retrospective study of patients with CAA (Boston criteria version 2.0) identified from the Aachen Memory Database and from in-hospital admission records, we compared CSF neurodegeneration markers and albumin ratio (a blood-brain barrier permeability marker) in patients with and without hemorrhagic markers.
resultsAmong 371 patients with CAA, 113 patients had hemorrhagic markers (30.5%). Lower amyloid beta (Aβ) 42, lower Aβ40, and higher albumin ratio were independently associated with the presence of hemorrhagic markers and an increasing number of lobar microbleeds. Cortical superficial siderosis and a higher imaging burden of CAA were associated with total tau protein. DISCUSSION: Presence of hemorrhagic markers in CAA patients is associated with lower CSF Aβ42 and Aβ40 and higher blood-brain barrier permeability. HIGHLIGHTS: New diagnostic criteria allow for the diagnosis of CAA without hemorrhagic markers.CAA hemorrhagic markers are associated with lower Aβ42 and Aβ40 in CSF.CAA hemorrhagic markers are associated with higher blood-brain barrier permeability.Higher imaging burden of CAA is associated with higher total tau protein in CSF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.